Biotransformations in Small-Molecule Pharmaceutical Development

Practical Methods for Biocatalysis and Biotransformations

Volumn , Issue , 2009, Pages 1-82

  Adams, Joseph P ^a   Collis, Andrew J ^a   Henderson, Richard K ^a   Sutton, Peter W ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Active pharmaceutical ingredient (API); Application of biocatalysis in pharmaceutical industry; Biocatalysis current status; Biotransformations in small molecule pharmaceutical development; Enzyme immobilization enzymatic DKR of thioester intermediate of odanacatib; Green chemistry use of biocatalysis in APIs manufacture; N acetyl D neuraminic acid (NANA) synthesized using NANA aldolase; New molecular entities (NMEs) and biologics, reaching the markets; Sparse incorporation of biocatalysts into process chemist's toolbox; Uridine diphosphate glucuronide transferase cycle

Indexed keywords

EID: 84860645614     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470748589.ch1     Document Type: Chapter

References (268)

1. PricewaterhouseCoopers, Pharma 2020: The vision, 2007. http://www.pwc.com/Extweb/onlineforms.nsf/docid/DA9F87D21EE8BCAA852575A5005B3484?opendocument&doc1/4vision.
2. McAndrews, P., Lilly sings a new tune: chorus unit brings high efficiency note to early R&D. The Pink Sheet, 69, 2007, 69.
3. Farina, V., Reeves, J.T., Senanayake, C.H. and Song, J.J., Asymmetric synthesis of active pharmaceutical ingredients. Chem. Rev., 106, 2006, 106-2734.
4. Agrawal, Y.K., Bhatt, H.G., Raval, H.G., Oza, P.M. and Gogoi, P.J., Chirality-a new era of therapeutics. Mini-Rev Med. Chem., 7, 2007, 7-451.
5. KPMG, Pressure points: risk management in the pharmaceuticals industry, 2006.
6. US Food and Drug Administration, Pharmaceutical current good manufacturing practices (cGMPs) for the 21st century-a risk-based approach: final report, 2004.
7. McKenzie, P., Kiang, S., Tom, J., Rubin, A.E. and Futran, M., Can pharmaceutical process development become high tech? Am. Inst. Chem. Eng., 52, 2006, 52-3990.
8. US Food and Drug Administration, Guidance for industry PAT-a framework for innovative pharmaceutical development, manufacturing, and quality assurance, 2004.
9. Rubin, A.E., Tummala, S., Both, D.A., Wang, C. and Delaney, E.J., Emerging technologies supporting chemical process R&D and their increasing impact on productivity in the pharmaceutical industry. Chem. Rev., 106, 2006, 106-2794.
10. Straathof, A.J.J., Panke, S. and Schmid, A., The production of fine chemicals by biotransformations. Curr. Opin. Biotechnol., 13, 2002, 13-548.
11. Liese, A., Seelbach K. and Wandrey C. (eds), Industrial Biotransformations. Wiley-VCH, 2006.
12. Pollard, D.J. and Woodley, J.M., Biocatalysis for pharmaceutical intermediates: the future is now. Trends Biotechnol., 25, 2007, 25-66.
13. Panke, S., Held, M. and Wubbolts, M., Trends and innovations in industrial biocatalysis for the production of fine chemicals. Curr. Opin. Biotechnol., 15, 2004, 15-272.
14. Carey, J.S., Laffan, D., Thomson, C. and Williams, M.T., Analysis of the reactions used for the preparation of drug candidate molecules. Org. Biomol. Chem., 4, 2006, 4-2337.
15. Breuer, M., Ditrich, K., Habicher, T., Hauer, B., Keßeler,M., Stürmer,R. and Zelinski, T., Industrial methods for the production of optically active intermediates. Angew. Chem. Int. Ed., 43, 2004, 43-788.
16. Constable, D.J.C., Dunn, P.J., Hayler, J.D., Humphrey, G.R., Leazer Jr, J.L., Linderman, R.J., Lorenz, K., Manley, J., Pearlman, B.A., Wells, A., Zaks, A. and Zhang, T.Y., Key green chemistry research areas-a perspective from pharmaceutical manufacturers. Green Chem., 9, 2007, 9-411.
17. Schoemaker, H.E., Mink, D., Wubbolt, M.G., Dispelling the myths-biocatalysis in industrial synthesis. Science, 299, 2003, 299-1694.
18. Vink, M.K.S. and Rozzell, J.D., Expanded opportunities for biocatalysis. PharmaChem, May 2006, 17-18.
19. Lefevre, F., Jarrin, C., Ginolhac, A., Auriol, D. and Nalin, R., Environmental metagenomics:an innovative resource for industrial biocatalysis. Biocatal. Biotrans., 25, 2007, 25-242.
20. Ferrer, M., Martínez-Abarca,F. and Golyshin, P.N., Mining genomes and 'metagenomes' for novel catalysts. Curr. Opin. Biotechnol., 16, 2005, 16-588.
21. Cowan, D.A., Arslanoglu, A., Burton, S.G., Baker, G.C., Cameron, R.A., Smith, J.J. and Meyer, Q., Metagenomics, gene discovery and the ideal biocatalyst. Biochem. Soc. Trans., 32, 2004, 32-298.
22. For some recent reviews on enzyme modification see: Reetz, M.T., Evolution in the test-tube as a means to creat selective biocatalysts. Chimia, 2007, 61, 100-103.
23. Sylvestre, J., Chautard, H., Cedrone, F. and Delcourt, M., Directed evolution of biocatalysts. Org. Proc. Res. Dev., 10, 2006, 10-562.
24. Hibbert, E.G. and Dalby, P.A., Directed evolution strategies for improved enzymatic performance. Microb. Cell Fact., 4, 2004, 4.
25. Otten, L.G. and Quax, W.J., Directed evolution: selecting today's biocatalysts. Biomol. Eng., 22, 2005, 22-1.
26. For some recent reviews on HTS, see: Aharoni, A., Griffiths, A.D. and Tawfik, D.S., Highthroughput screens and selections of enzyme-encoding genes. Curr. Opin. Chem. Biol., 9, 2005, 9-210.
27. Reymond, J. and Babiak, P., Screening systems. Adv. Biochem. Eng Biotechnol., 105, 2007, 105-31.
28. Fox, R.J., Davis, S.C., Mundorff, E.C., Newman, L.M., Gavrilovic, V., Ma, S.K., Chung, L.M., Ching, C., Tam, S., Muley, S., Grate, J., Gruber, J., Whitman, J.C., Sheldon, R.A. and Huisman, G.W., Improving catalytic function by ProSAR-driven enzyme evolution. Nat. Biotechnol., 25, 2007, 25-338.
29. Hilterhaus, L. and Liese, A., Building blocks. Adv. Biochem. Eng. Biotechnol., 105, 2007, 105-133.
30. Grossman, S.J., Overview: drug metabolism in the modern pharmaceutical industry. In Drug Metabolism in Drug Design and Development, Zhang, D., Zhu, M. and Humphreys, W.G. (eds). J. Wiley & Sons, Inc., 2008, pp. 3-13.
31. Testa, B. and Krämer, S. D., The biochemistry of drug metabolism-an introduction part 1. Principles and overview. Chem. Biodiv., 2006, 3, 1053-1101 and references cited therein.
32. Azerad, R., Microbial models for drug metabolism. Adv. Biochem. Eng. Biotechnol., 63, 1999, 63-169.
33. Smith, R.V. and Rosazza, J.P., Microbial models of mammalian metabolism. J. Pharm. Sci., 64, 1975, 64-1737.
34. Alexandre, V., Ladril, S., Maurs, M. and Azerad, R., Microbial models of animal drug metabolism Part 5. Microbial preparation of human hydroxylated metabolites of irbesartan. J. Mol. Catal. B: Enzymatic, 29, 2004, 29-173.
35. For a recent review on microbial preparation of metabolites, see Venisetty, R.K. and Ciddi, V., Application of microbial biotransformation for the new drug discovery using natural drugs as substrates. Curr. Pharm. Biotechnol., 4, 2003, 4-153.
36. Testa, B. and Krämer, S.D., The biochemistry of drug metabolism-an introduction part 2. Redox reactions and their enzymes. Chem. Biodiv., 4, 2007, 4-257.
37. Smith, D.A., Ackland, M.J. and Jones, B.C., Properties of cytochrome P450 isoenzymes and their substrates. Part 2: properties of cytochrome P450 substrates. Drug Discov. Today, 1997, 2, 479-486 and references cited therein.
38. Hanlon, S.P., Friedburg, T., Wolf, C.R., Ghisalba, O. and Kittelmann, M., Recombinant yeast and bacteria that express human P450s: bioreactors for drug discovery, development, and biotechnology. In Modern Biooxidation. Enzymes, Reactions and Applications. Schmid, R.D. and Urlacher, V.B. (eds). Wiley-VCH: Weinheim, 2007, pp. 233-252.
39. Crespi, C.L. and Miller, V.P., The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol. Therap., 84, 1999, 84-121.
40. Schwaneberg, U., Otey, C., Cirino, P.C., Farinos, E. and Arnold, F.H., Cost-effective whole-cell assay for laboratory evolution of hydroxylases in Escherichia coli. J. Biomol. Screen., 6, 2001, 6-111.
41. Ghisalba, O. and Kittelmann, M., Preparation of drug metabolites using fungal and bacterial strains. In Modern Biooxidation, Schmid, R.D. and Urlacher, V. (eds). Wiley-VCH: Weinheim, 2007, pp. 211-232.
42. This volume, Section 12.3, Kittelmann et al.
43. Wong, J.W., Watson Jr, H.A., Bouressa, J.F., Burns, M.P., Cawley, J.J., Doro, A.E., Guzek, D.B., Hintz, M.A., McCormick, E.L., Scully, D.A., Siderewicz, J.M., Taylor, W.J., Truesdell, S.J. and Wax, R.G. Biocatalytic oxidation of 2-methylquinoxaline to 2-quinoxalinecarboxylic acid. Org. Proc. Res. Dev., 2002, 6, 477-481.
44. Stachulski, A.V. and Jenkins, G.N., The synthesis of O-glucuronides. Nat. Prod. Rep., 15, 1998, 15-173.
45. Chiu, S.H. and Huskey, S.W., Species differences in N-glucuronidation. Drug Metab. Dispos., 26, 1998, 26-838.
46. Kittelmann, M., Rheinegger, U., Espigat, A., Oberer, L., Aichholz, R., Francotte, E. and Ghisalba, O., Preparative enzymatic synthesis of the acylglucuronide of mycophenolic acid. Adv. Synth. Catal., 345, 2003, 345-825.
47. Baratto, L., Candido, A., Marzorati, M., Sagui, F., Riva, S. and Danieli, B., Laccase-mediated oxidation of natural glycosides. J. Mol. Catal. B: Enzymatic, 39, 2006, 39-3.
48. Fabbrini, M., Galli, C., Gentili, P. andMacchitella, D., An oxidation of alcohols by oxygen with the enzyme laccase and mediation by TEMPO. Tetrahedron Lett., 42, 2001, 42-7551.
49. Niku-Paavola,M.-L. and Viikari, L., Enzymatic oxidation of alkenes. J. Mol. Catal. B: Enzymatic, 10, 2000, 10-435.
50. Potthast, A., Rosenau, T., Chen,C.-L. and Gratzl, J.S., Selective enzymatic oxidation of aromatic methyl groups to aldehydes. J. Org. Chem. 1995, 60, 4320-4321.
51. Wong, C.-H. and Whitesides, G.M., Enzymes in synthetic organic chemistry. In Tetrahedron Organic Chemistry Series, Baldwin, J.E. and Magnus, P.D. (eds), Pergamon, 1994.
52. Newman, D.J., Cragg, G.M. and O'Keefe, B.R., Biopharmaceutical drugs from natural sources. In Modern Biopharmaceuticals, Knäblein, J. (ed). Wiley-VCH: Weinheim, 2005, pp. 451-496.
53. Walsh, G. and Jefferis, R., Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol., 24, 2006, 24-1241.
54. Meyer, A., Pellaux, R. and Panke, S. Bioengineering novel in vitro metabolic pathways using synthetic biology. Curr. Opin. Microbiol., 2007, 10, 246-253.
55. Koeller, K.M. and Wong, C.-H., Synthesis of complex carbohydrates and glycoconjugates:enzyme-based and programmable one-pot strategies. Chem. Rev. 2000, 100, 4465-4493.
56. Khmelnitsky, Y.L., Current strategies for in vitro protein glycosylation. J. Mol. Catal. B, 31, 2004, 31-73.
57. ö hrlein, R., Glycosyltransferase-catalysed synthesis of non-natural oligosaccharides. Topics Curr. Chem., 200, 1999, 200-227.
58. Rowan, A.S. and Hamilton, C.J., Recent developments in preparative enzymatic syntheses of carbohydrates. Nat. Prod. Rep., 2006, 23, 412-443 and references cited therein.
59. Ullman, C.G. and Perkins, S.J., A classification of nucleotide diphospho-sugar glycosyltransferases based on amino acid sequence similarities. Biochem. J., 326, 1997, 326-929.
60. Shao, H., He, X., Achnine, L., Blount, J.W., Dixon, R.A. and Wang, X., Crystal structures of a multifunctional triterpene/flavonoid glycosyltransferase from Medicago truncatula. The Plant Cell, 17, 2005, 17-3141.
61. Lim, E.-K., Ashford, D.A., Hou, B., Jackson, R.G. and Bowles, D.J., Biotechnol. Bioeng., 87, 2004, 87-623.
62. Perusino, G., Cobucci-Ponzano, B., Rossi, M. and Moracci, M., Recent advances in the oligosaccharide synthesis promoted by catalytically engineered glycosidases. Adv. Synth. Catal., 347, 2005, 347-941.
63. Mackenzie, L.F., Wang, Q., Warren, R.A.J. and Withers, S.G., Glycosynthases: mutant glycosidases for oligosaccharide synthesis. J. Am. Chem. Soc., 120, 1998, 120-5583.
64. Spence, D.W. and Ramsden, M., Penicillin acylases. In Industrial Enzymes, Polaina, J. and MacCabe, A.P. (eds). Springer: Dordrecht, 2007, pp. 583-597.
65. Henderson R.K., Jiménez-González C., Preston C., Constable D.J.C. and Woodley, J.M., EHS & LCA assessment for 7-ACA synthesis. A case study for comparing biocatalytic & chemical synthesis. Ind. Biotechnol., 4, 2008, 4-180.
66. Fildes, R.A., Potts, J.R. and Farthing, J.E., Process for preparing cephalosporin derivatives. PCT Appl., 1974, US 3,801,458.
67. Matsuda, A., Matsuyama, K., Yamamoto, K., Ichikawa, S. and Komatsu, K.-I., Cloning and characterization of the genes for two distinct cephalosporin acylases from a Pseudomonas strain. J. Bacteriol., 169, 1987, 169-5815.
68. Matsumoto, K., Production of 6-APA, 7-ACA and 7-ADCA by immobilised penicillin and cephalosporin amidases. Bioproc. Technol. 1993, 16, 67-88.
69. Brakhage, A.A., Molecular regulation of b-lactam biosynthesis in filamentous fungi. Microbiol. Mol. Biol. Rev., 62, 1998, 62-547.
70. Conder, M.J., Crawford, L., McAda, P.C. and Rambosek, J.A., Novel bioprocess for preparing 7-ADCA. PCT Appl., 1992, EP 0532341 A1.
71. Sheldon, R.A. and van Rantwijk, F., Biocatalysis for sustainable organic synthesis. Aust. J. Chem., 57, 2004, 57-281.
72. Fernández-Lafuente,R., Rosell, C.M., Piatkowska, B. and Guisán, J.M., Synthesis of antibiotics (cephaloglycin) catalyzed by penicillin G acylase: evaluation and optimization of different synthetic approaches. Enzyme Microb. Technol., 19, 1996, 19-9.
73. Kallenberg, A.I., van Rantwijk, F. and Sheldon, R.A., Immobilization of penicillin G acylase: the key to optimum performance. Adv. Synth. Catal., 347, 2005, 347-905.
74. Schroen, C.G.P.H., Nierstrasz, V.A., Bosma, R., Kroon, P.J., Tjeerdsma, P.S., DeVroom, E., VanderLaan, J.M., Moody, H.M., Beeftink, H.H., Janssen, A.E.M. and Tramper, J., Integrated reactor concepts for the enzymatic kinetic synthesis of cephalexin. Biotech. Bioeng., 80, 2002, 80-144.
75. Kim, I., Song, X., Vig, B.S., Mittal, S., Shin, H.-C., Lorenzi, P.J. and Amidon, G.L., A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol. Pharm., 1, 2004, 1-117.
76. Tamarez, M., Morgan, B., Wong, G.S.K., Tong, W., Bennett, F., Lovey, R., McCormick, J.L. and Zaks, A., Pilot-scale lipase-catalyzed regioselective acylation of ribavirin in anhydrous media in the synthesis of a novel prodrug intermediate. Org. Proc. Res. Dev., 7, 2003, 7-951.
77. Zaks, A. and Klibanov, A.M., Enzymatic catalysis in nonaqueous solvent. J. Biol. Chem., 263, 1988, 263-3194.
78. Klibanov, A.M., Asymmetric enzymatic oxidoreductions in organic solvents. Curr. Opin. Biotechnol., 14, 2003, 14-427.
79. Ferrero, M. and Gotor, V., Biocatalytic selective modifications of conventional nucleosides, carbocyclic nucleosides, and C-nucleosides. Chem. Rev., 2000, 100, 4319-4347 and references cited therein.
80. Tamarez, M., Morgan, B., Wong, G.S.K., Tong, W., Bennett, F., Lovey, R., McCormick, J.L. and Zaks, A., Pilot-scale lipase-catalyzed regioselective acylation of ribavirin in anhydrous media in the synthesis of a novel prodrug intermediate. Org. Proc. Res. Dev., 7, 2003, 7-951.
81. Mahmoudian, M., Eaddy, J. and Dawson, M., Enzymic acylation of 506U78 (2-amino-9-β-Darabinofuranosyl-6-methoxy-9H-purine), a powerful new anti-leukaemic agent. Biotechnol. Appl. Biochem., 29, 1999, 29-229.
82. Hanson, R.L., Shi, Z., Brzozowski, D.B., Banerjee, A., Kissick, T.P., Singh, J., Pullockaran, A.J., North, J.T., Fan, J., Howell, J., Durand, S.C., Montana, M.A., Kronenthal, D.R., Mueller, R.H. and Patel, R.N., Regioselective enzymatic aminoacylation of lobucavir to give an intermediate for lobucavir prodrug. Bioorg. Med. Chem., 8, 2000, 8-2681.
83. Manzoni, M. and Rollini, M., Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotechnol., 58, 2002, 58-555.
84. Sleteinger, M., Verhoeven, T.R. and Volante, R.P., Process for C-methylation of 2-methylbutyrates. US PCT Appl., 1986, US 4,582,915.
85. Askin, D., Verhoeven, T.R., Liu, T.M.-H. and Shinkai, I., Synthesis of synvinolin: extremely high conversion alkylation of an ester enolate. J. Org. Chem., 56, 1991, 56-4929.
86. Schimmel, T.G., Borneman,W.S. and Conder, M.J., Purification and characterization of a lovastatin esterase from Clonostachys compactiuscula. Appl. Environ. Microbiol., 63, 1997, 63-1307.
87. Xie, X. and Tang, Y., Efficient synthesis of simvastatin by use of whole-cell biocatalysis. Appl. Environ. Microbiol., 73, 2007, 73-2054.
88. Xie, X., Wong, W.W. and Tang, Y., Improving simvastatin bioconversion in Escherichia coli by deletion of bioH. Metabol. Eng., 9, 2007, 9-379.
89. Kern, A., Tilley, E., Hunter, I.S., Legisa, M. and Glieder, A., Engineering primary metabolic pathways of industrial micro-organisms. J. Biotechnol., 129, 2007, 129-6.
90. Sørensen, H.P. and Mortensen, K.K., Advanced genetic strategies for recombinant protein expression in Escherichia coli. J. Biotechnol., 115, 2005, 115-113.
91. McCandliss, R.J. and Anderson, D.M., Fermentation process for the production of pyrimidine deoxyribonucleosides. PCT Int. Appl., 1991, WO91/09130.
92. Anderson, D. M., Liu, L., Podkovyrov, S. and Wang, B., PCT Int. Appl., 2001, WO2001002580 A1.
93. Anderson, D.M., Collis, A.J., Liu, L., Podkovyrov, S. and Preston, C., Thymidine production in various strains/constructs. PCT Int. Appl., 2007, WO2007/090810 A1.
94. Roth, B.D., The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog. Med. Chem., 2002, 40, 1-22 and references cited therein.
95. Müller, M., Chemoenzymatic synthesis of building blocks for statin side chains. Angew. Chem. Int. Ed., 44, 2005, 44-362.
96. Fox, R.J., Davis, S.C., Mundorff, E.C., Newman, L.M., Gavrilovic, V., Ma, S.K., Chung, L.M., Ching, C., Tam, S., Muley, S., Grate, J., Gruber, J., Whitman, J.C., Sheldon, R.A. and Huisman, G.W., Improving catalytic function by ProSAR-driven enzyme evolution. Nat. Biotechnol., 25, 2007, 25-338.
97. Lewkowicz, E.S. and Iribarren, A.M., Nucleoside phosphorylase. Curr. Org. Chem., 2006, 10, 1197-1215;
98. Utagawa, T., Enzymatic preparation of nucleoside antibiotics. J. Mol. Catal. B, 6, 1999, 6-215.
99. Shirae, H., Yokozeki, K., Uchiyama, M. and Kubota, K., Enzymatic production of ribavirin from purine nucleosides by Brevibacterium acetylicum. Agric. Biol. Chem., 52, 1988, 52-1777.
100. Krenitsky, T.A., Koszalka, G.W. and Tuttle, J.V., Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylases. Biochemistry, 20, 1981, 20-3615.
101. Krenitsky, T.A., Elion, G.B. and Rideout, J.L., Enzymatic synthesis of arabinonucleosides, Eur. PCT Appl., 1979, EP 0002192;
102. Krenitsky, T.A., Koszalka, G.W., Tuttle, J.V., Rideout, J.L. and Elion, G.B., An enzymatic synthesis of purine D-arabinonucleosides. Carbohydrate Res., 97, 1981, 97-139.
103. Komura, H., Yoshino, T. and Ishido, Y., Synthetic studies by the use of carbonates. II. Easy method of preparing cyclic carbonates of polyhydroxy compounds by transesterification with ethylene carbonate. Bull. Chem. Soc., 46, 1973, 46-550.
104. Averett, D.R., Koszalka, G.W., Fyfe, J.A., Roberts, G.B., Purifoy, D.J.M. and Krenitsky, T.A., 6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus. Antimicrob. Agents Chemother. 1991, 35, 851-857.
105. Mahmoudian, M., Development of bioprocesses for the generation of anti-inflammatory, antiviral and anti-leukaemic agents. Focus Biotechnol. 2001, 1, 249-265.
106. Utagawa, T., Morisawa, H., Yoshinaga, F., Yamazaki, A., Misugi, K. and Hirose, Y., Microbiological synthesis of adenine arabinoside. Agric. Biol. Chem., 49, 1985, 49-1053.
107. Herbal, K., Kitteringham, J., Voyle, M. and Whitehead, A.J., Synthesis of the enantiomer of nelarabine. Tetrahedron Lett., 46, 2005, 46-2961.
108. Warren, L. and Felsenfeld, H., Biosynthesis of N-acetylneuraminic acid. Biochem. Biophys. Res. Commun., 4, 1961, 4-232.
109. Tabata, K., Koizumi, S., Endo, T. and Ozaki, A., Production of N-acetyl-D-neuraminic acid by coupling bacteria expressing N-acetyl-D-glucosamine 2-epimerase and N-acetyl-D-neuraminic acid synthetase. Enzyme Microb. Technol. 2002, 30, 327-333.
110. Samain, E., High yield production of sialic acid (Neu5Ac) by fermentation. PCT Int. Appl., 2008,WO 2008040717 A2;
111. Lundgren, B.R. and Boddy, C.N., Sialic acid and N-acyl sialic acid analog production by fermentation of metabolically and genetically engineered Escherichia coli. Org. Biomol. Chem., 5, 2007, 5-1903.
112. Comb, D.G. and Roseman, S., Composition and enzymic synthesis of N-acetylneuraminic acid (sialic acid). J. Am. Chem. Soc., 80, 1958, 80-497.
113. Cipolletti, G., Tamerlani, G., Lombardi, I. and Bartalucci, D., Process for the preparation of N-acetyl-D-mannosamine monohydrate. PCT Int. Appl., 2007, WO 2007135086 A1.
114. Mahmoudian, M., Noble, D., Drake, C.S., Middleton, R.F., Montgomery, D.S., Piercey, J.E., Ramlakhan, D., Todd, M. and Dawson, M.J., An efficient process for production of N-acetylneuraminic acid using N-acetylneuraminic acid aldolase. Enzyme Microb. Technol. 1997, 20, 393-400.
115. Kragl, U., Wandrey, C., Ghisalba, O. and Gygax, D., Enzymic preparation of N-acetyl neuraminic aci. Ger. Offen. 1991, DE 3937891 A1;
116. Maru, I., Ohnishi, J., Ohta, Y. and Tsukada, Y., Why is sialic acid attracting interest now? Complete enzymatic synthesis of sialic acid with N-acylglucosamine 2-epimerase. J. Biosci. Bioeng., 2002, 93, 258-265;
117. Maru, I., Ohnishi, J., Ohta, Y. and Tsukada, Y., Simple and large-scale production of N-acetylneuraminic acid from N-acetyl-D-glucosamine and pyruvate using N-acetyl-D-glucosamine 2-epimerase and N-acetylneuraminate lyase. Carbohydrate Res., 306, 1998, 306-575.
118. Kragl, U., Kittelmann, M., Ghisalba, O. and Wandrey, C., N-Acetylneuramic acid: from a rare chemical from natural sources to a multikilogram enzymatic synthesis for industrial application. Ann. N. Y. Acad. Sci., 750, 1995, 750-300.
119. García-Urdiales, E., Alfonso, I. and Gotor, V., Enantioselective enzymatic desymmetrizations in organic synthesis. Chem. Rev., 105, 2005, 105-313.
120. Hasan, F., Shah, A.A. and Hameed, A. Industrial applications of microbial lipases. Enzyme Microb. Technol., 2006, 39, 235-251.
121. Maurer, K.-H., Detergent proteases. Curr. Opin. Biotechnol., 15, 2004, 15-330.
122. Gupta, R., Beg, Q.K. and Lorenz, P., Bacterial alkaline proteases: molecular approaches and industrial applications. Appl. Microbiol. Biotechnol., 59, 2002, 59-15.
123. Martinez, C.A., Hu, S., Dumond, Y., Tao, J., Kelleher, P. and Tully, L., Development of a chemoenzymatic manufacturing process for pregabalin. Org. Proc. Res. Dev., 12, 2008, 12-392.
124. Canoy, W.L., Cooley, B.E., Corona, J.A., Lovelace, T.C., Millar, A., Weber, A.M., Xie, S. and Zhang, Y., Efficient synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol from glycolaldehyde. Org. Lett., 2008, 10, 1103-1106 and references cited therein.
125. Yu, R.H., Polniaszek, R.P., Becker, M.W., Cook, C.M. and Yu, L.H.L., Research and development of an efficient synthesis of hexahydrofuro[2,3-b]furan-3-ol moiety-a key component of the HIV protease inhibitor candidates. Org. Proc. Res. Dev., 11, 2007, 11-972.
126. Doan, B.D., Davis, R.D. and Lovelace, T.C., Process for preparing intermediates for HIV aspartyl protease inhibitors, particularly (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol and its (3R,3aS,6aR)-enantiomer. PCT Int. Appl., 2003, WO 2003024974 A2.
127. Roberts, J., A commercially viable route and process to HIV PI GW640385X. Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, 2003, September 7-11.
128. Vaidyanathan, R., Hesmondhalgh, L. and Hu, S., A chemoenzymatic synthesis of an androgen receptor antagonist. Org. Proc. Res. Dev., 11, 2007, 11-903.
129. Terao, Y., Tsuji, K., Murata, M., Achiwa, K., Nishio, T., Watanabe, N. and Seto, K., Facile process for enzymatic resolution of racemic alcohols. Chem. Pharm. Bull., 37, 1989, 37-1653.
130. Andrews, I.P., Atkins, R.J., Breen, G.F., Carey, J.S., Forth, M.A., Morgan, D.O., Shamji, A., Share, A.C., Smith, S.A.C., Walsgrove, T.C. and Wells, A.S., The development of a manufacturing route for the GPIIb/IIIa receptor antagonist SB-214857-. Part 1: synthesis of the key intermediate 2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid methyl ester, SB-235349. Org. Proc. Res. Dev., 2003, 7, 655-662;
131. Atkins, R.J., Banks, A., Bellingham, R.K., Breen, G.F., Carey, J.S., Etridge, S.K., Hayes, J.F., Hussain, N., Morgan, D.O., Oxley, P., Passey, S.C., Walsgrove, T.C. and Wells, A.S., The development of a manufacturing route for the GPIIb/IIIa receptor antagonist SB-214857-A. Part 2: conversion of the key intermediate SB-235349 to SB-214857-A. Org. Proc. Res. Dev., 7, 2003, 7-663.
132. Roberts, N.J., Seago, A., Carey, J.S., Freer, R., Preston, C. and Lye, G.J., Lipase catalysed resolution of the lotrafiban intermediate 2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid methyl ester in ionic liquids: comparison to the industrial t-butanol process. Green Chem., 6, 2004, 6-475.
133. Butters, M., Catterick, D., Craig, A., Curzons, A., Dale, D., Gillmore, A., Green, S.P., Marziano, I., Sherlock, J.-P. and White, W., Critical assessment of pharmaceutical processess-a rationale for changing the synthetic route. Chem. Rev., 106, 2006, 106-3002.
134. Casu, F., Chiacchio, M.A., Romeo, R. and Gumina, G., Chiral synthesis of heterosubstituted nucleoside analogs from non-carbohydrate precursors. Curr. Org. Chem., 11, 2007, 11-1017.
135. Mahmoudian, M., Baines, B.S., Drake, C.S., Hale, R.S., Jones, P., Piercey, J.E., Montgomery, D.S., Purvis, I.J., Storer, R., Dawson, M.J. and Lawrence, G.C., Enzymatic production of optically pure (20R-cis)-20-deoxy-30-thiacytidine (3TC, lamivudine): a potent anti-HIV agent. Enzyme Microb. Technol., 15, 1993, 15-749.
136. Munch-Petersen, A., Nygaard, P., Hammer-Jespersen, K. and Fiil, N., Mutants constitutive for nucleoside-catabolizing enzymes in Escherichia coli K 12. Eur. J. Biochem., 27, 1972, 27-208.
137. Mahmoudian, M. and Dawson, M.J., Chemoenzymic production of the antiviral agent EpivirTM. In Biotechnology of Antibiotics, Strohl, W.R. (ed.). Dekker: New York, 1997, pp. 753-777.
138. Solares, L.F., Brieva, R., Quirós, M., Llorente, I., Bayod, M. and Gotor, V., Enzymatic resolution of a quaternary stereogenic centre as the key step in the synthesis of (S)-({thorn})-citalopram. Tetrahedron Asymm., 15, 2004, 15-341.
139. Mateja Pogorevc, M. and Faber, K., Biocatalytic resolution of sterically hindered alcohols, carboxylic acids and esters containing fully substituted chiral centers by hydrolytic enzymes. J. Mol. Catal. B, 2000, 10, 357-376 and references cited therein.
140. Taylor, S.J.C., Sutherland, A.G., Lee, C., Wisdom, R., Thomas, S., Roberts, S.M. and Evans, C., Chemoenzymatic synthesis of (α)-carbovir utilizing a whole cell catalysed resolution of 2-azabicyclo[2.2.1 ]hept-5-en-3-one. J. Chem. Soc. Chem. Commun., 1990, 1120-1121;
141. Evans, C.T., Roberts, S.M., Shoberu, K.A. and Sutherland, A.G., Potential use of carbocyclic nucleosides for the treatment of AIDS: chemo-enzymatic syntheses of the enantiomers of carbovir. J. Chem. Soc. Perkin Trans. 1, 1992, 589-592.
142. Taylor, S.J.C, McCague, R., Wisdom, R., Lee, C., Dickson, K., Ruecroft, G., O'Brien, F., Littlechild, J., Bevan, J., Roberts, S.M. and Evans, C.T., Development of the biocatalytic resolution of 2-azabicyclo [2,2,1] hept-5-en-3-one as an entry to single-enantiomer carbocyclic nucleosides. Tetrahedron Asymm., 4, 1993, 4-1117.
143. Mahmoudian, M., Lowdon, A., Jones, M., Dawson, M. and Wallis, C., A practical enzymatic procedure for the resolution of N-substituted 2-azabicyclo[2.2.1]hept-5-en-3-one. Tetrahedron Asymm. 1999, 10, 1201-1206.
144. Carnell, A.J., Desymmetrisation of prochiral ketones using lipases. J. Mol. Catal. B, 2002, 19-20, 83-92.
145. Allan, G., Carnell, A.J., Escudero Hernandez, M.L. and Pettman, A., Chemoenzymatic synthesis of a tachykinin NK-2 antagonist. Tetrahedron, 57, 2001, 57-8193.
146. Carnell, A.J., Barkely, J. and Singh, A., Desymmetrisation of prochiral ketones by catalytic enantioselective hydrolysis of their enol esters using enzyme. Tetrahedron Lett., 1997, 38, 7781-7784;
147. Allan, G.R., Carnell, A.J. and Kroutil, W., One-pot deracemisation of an enol acetate derived from a prochiral cyclohexanone. Tetrahedron Lett., 42, 2001, 42-5959.
148. Pellissier, H., Recent developments in dynamic kinetic resolu. Tetrahedron, 2008, 64, 1563-1601;
149. Turner, N.J., Enzyme catalysed deracemisation and dynamic kinetic resolution reactions. Curr. Opin. Chem. Biol., 2004, 8, 114-119;
150. Gruber, C.C., Lavandera, I., Faber, K. and Kroutil, W., From a racemate to a single enantiomer: deracemisation by stereoinversion. Adv. Synth. Catal., 2006, 348, 1789-1805;
151. Pellissier, H., Dynamic kinetic resolution. Tetrahedron, 2003, 59, 8291-8327;
152. Pámies, O. and Bäckvall, J.-E., Combination of enzymes and metal catalysts. A powerful approach in asymmetric catalysis. Chem. Rev., 103, 2003, 103-3247.
153. Hughes, G., O'Shea, P.D., Devine, P.N., Foster, B., Gauthier, D., Limanto, J., Truppo, M., Pollard, D., Naber, J., McKay, D.J. and Volante, R.P., The discovery and development of odanacatib: a selective inhibitor of cathepsin K for the treatment of osteoporosis. In 25th SCI Process Development Symposium, 2007.
154. Gu, R.-L., Lee, I.S. and Sih, C.J., Chemo-enzymatic asymmetric synthesis of amino acid. Enantioselective hydrolyses of 2-phenyl-oxazolin-5-ones. Tetrahedron Lett., 1992, 33, 1953-1956;
155. Crich, J., Brieva, R., Marquart, P., Gu, R.-L., Flemming, S. and Sih, C.J., Enzymic asymmetric synthesis of α-amino acids. Enantioselective cleavage of 4-substituted oxazolin-5-ones and thiazolin-5-ones. J. Org. Chem., 58, 1993, 58-3252.
156. Limanto, J., Shaifee, A., Devine, P.N., Upadhyay, V., Desmond, R.A., Foster, B.R., Gauthier Jr, D.R., Reamer, R.A. and Volante, R.P., An efficient chemoenzymatic approach to (S)-γ-fluoroleucine ethyl ester. J. Org. Chem., 70, 2005, 70-2372.
157. Madsen, R., Roberts, C. and Fraser-Reid, B., The pent-4-enoyl group: a novel amine-protecting group that is readily cleaved under mild conditions. J. Org. Chem., 60, 1995, 60-7920.
158. Truppo, M.D. and Moore, J.C., Process for making fluoroleucine ethyl esters. US PCT Appl., 2007, US 2007/0059812 A1.
159. Pesti, J.A., Yin, J., Zhang, L.-H. and Anzalone, L., Reversible Michael reaction-enzymatic hydrolysis: a new variant of dynamic resolutio. J. Am. Chem. Soc., 2001, 123, 11075-11076;
160. Pesti, J.A., Yin, J., Zhang, L.-H., Anzalone, L., Waltermire, R.E., Ma, P., Gorko, E., Confalone, P.N., Fortunak, J., Silverman, C., Blackwell, J., Chung, J.C., Hrytsak, M.D., Cooke, M., Powell, L. and Ray, C., Efficient preparation of a key intermediate in the synthesis of roxifiban by enzymatic dynamic kinetic resolution on large scale. Org. Proc. Res. Dev., 8, 2004, 8-22.
161. Miyazawa, T., Kurita, S., Ueji, S., Yamada, T. and Shigeru, K., Resolution of mandelic acids by lipase-catalyzed transesterifications in organic media: inversion of enantioselectivity mediated by the acyl donor. J. Chem. Soc. Perkin Trans. 1, 18, 1992, 18-2253.
162. Gröger, H., Enzymatic routes to enantiomerically pure aromatic α-hydroxy carboxylic acids: a further example for the diversity of biocatalysis. Adv. Synth. Catal., 343, 2001, 343-547.
163. Huang, H.-R., Xu, J.-H., Xu, Y., Pan, J. and Liu, X., Preparation of (S)-mandelic acids by enantioselective degradation of racemates with a new isolate Pseudomonas putida ECU1009. Tetrahedron Asymm., 16, 2005, 16-2113.
164. DeSantis, G., Zhu, Z., Greenberg, W.A., Wong, K., Chaplin, J., Hanson, S.R., Farwell, B., Nicholson, L.W., Rand, C.L., Weiner, D.P., Robertson, D.E. and Burk, M.J., An enzyme library approach to biocatalysis: development of nitrilases for enantioselective production of carboxylic acid derivatives. J. Am. Chem. Soc., 124, 2002, 124-9024.
165. Saksena, A.K., Girijavallabhan, V.M., Lovey, R.G., Pike, R.E., Desai, J.A., Ganguly, A.K., Hare, R.S., Loebenberg, D., Cacciapuoti, A. and Parmegiani, R.M., Enantioselective synthesis of the optical isomers of broad-spectrum orally active antifungal azoles, SCH 42538 and SCH 45012. Biorg. Med. Chem. Lett., 4, 1994, 4-2023.
166. Morgan, B., Dodds, D.R., Zaks, A., Andrews, D.R. and Klesse, R., Enzymatic desymmetrisation of prochiral 2-substituted-1,3-propanediols: a practical chemoenzymatic synthesis of a key precursor of SCH51048, a broad-spectrum orally active antifungal agent. J. Org. Chem., 62, 1997, 62-7736.
167. Schmid, R.D. and Verger, R., Lipases: interfacial enzymes with attractive applications. Angew. Chem. Int. Ed., 1998, 37, 1608-1633 and references cited therein.
168. Homann M.J., Suen W.-C., Zhang, N. and Zaks, A., Comparative analysis of chemical and biocatalytic syntheses of drug intermediates. In Biocatalysis in the Pharmaceutical and Biotechnology Industries, Patel, R.N. (ed.), CRC Press, 2007, pp. 645-659 and references cited therein.
169. Maddrell, S.J., Turner, N.J., Kerridge, A., Willetts, A.J. and Crosby, J., Nitrile hydratase enzymes in organic synthesis: enantioselective synthesis of the lactone moiety of the mevinic acids. Tetrahedron Lett., 37, 1996, 37-6001.
170. Bergeron, S., Chaplin, D.A., Edwards, J.H., Ellis, B.S.W., Hill, C.L., Holt-Tiffin, K., Knight, J.R., Mahoney, T., Osborne, A.P. and Ruecroft, G., Nitrilase-catalysed desymmetrisation of 3-hydroxyglutaronitrile: preparation of a statin side-chain intermediate. Org. Proc. Res. Dev., 10, 2006, 10-661.
171. DeSantis, G., Wong, K., Farwell, B., Chatman, K., Zhu, Z., Tomlinson, G., Huang, H., Tan, X., Bibbs, L., Chen, P., Kretz, K. and Burk, M.J., Creation of a productive, highly enantioselective nitrilase through gene site saturation mutagenesis (GSSM). J. Am. Chem. Soc., 125, 2003, 125-11476.
172. Homann, M.J., Vail, R.B., Previte, E., Tamarez, M., Morgan, B., Dodds, D.R. and Zaks, A., Rapid identification of enantioselective ketone reductions using targeted microbial libraries. Tetrahedron, 60, 2004, 60-789.
173. Barbieri, C., Caruso, E., D'Arrigo, P., Fantoni, G.P. and Servi, S., Chemo-enzymatic synthesis of (R)-and (S)-3,4-dichlorophenylbutanolide intermediate in the synthesis of sertraline. Tetrahedron Asymm. 1999, 10, 3931-3937.
174. Leonida, M.D., Redox enzymes used in chiral syntheses coupled to coenzyme regeneration. Curr. Med. Chem., 8, 2001, 8-345.
175. Eckstein, M., Daubmann, T. and Kragl, U., Recent developments in NAD(P)H regeneration for enzymatic reductions in one-and two-phase systems. Biocatal. Biotrans., 22, 2004, 22-89.
176. Davis, S.C., Grate, J.H., Gray, D.R., Gruber, J.M., Huisman, G.W., Ma, S.K., Newman, L.M., Sheldon, R. and Wang, L.A., Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives. PCT Int. Appl., 2004, WO 2004015132 A2.
177. Ema, T., Okita, N., Ide, S. and Sakai, T., Highly enantioselective and efficient synthesis of methyl (R)-o-chloromandelate with recombinant E. coli: toward practical and green access to clopidogrel. Org. Biomol. Chem., 5, 2007, 5-1175.
178. King, A.O., Corely, E.G., Anderson, R.K., Larsen, R.D., Verhoeven, T.R., Reider, P.J., Xiang, Y.B., Belley, M., Leblane, Y., Labelle, M., Prasit, P. and Zamboni, R.J., An efficient synthesis of LTD4 antagonist L-699,392. J. Org. Chem., 58, 1993, 58-3731.
179. Shafiee, A., Motamedi, H. and King, A., Purification, characterization and immobilization of an NADPH-dependent enzyme involved in the chiral specific reduction of the keto ester M, an intermediate in the synthesis of an anti-asthma drug, montelukast, from Microbacterium campoquemadoensis (MB5614). Appl. Microbiol. Biotechnol., 49, 1998, 49-709.
180. Ulijn, R,V., De Martin, L., Gardossi L. and Halling, P.J., Biocatalysis in reaction mixtures with undissolved solid substrates and products. Curr. Org. Chem., 7, 2003, 7-1333.
181. Rozzell, D., Enzymatic production of the key montelukast intermediate. Spec. Chem.Mag., 2008, April, 36-38.
182. Reddy, G.K., Gralla, R.J. and Hesketh, P.J., Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support. Cancer Ther., 3, 2006, 3-140.
183. Gelo-Pujic, M., Le Guyader, F. and Schlama, T., Microbial and homogenous asymmetric catalysis in the reduction of 1-[3,5-bis(trifluoromethyl)phenyl]ethanone. Tetrahedron Asymm. 2006, 17, 2000-2005.
184. Pollard, D., Truppo, M., Pollard, J., Chen, C.-Y. and Moore, J., Effective synthesis of (S)-3,5-bistrifluoromethylphenyl ethanol by asymmetric enzymatic reduction. Tetrahedron Asymm. 2006, 17, 554-559.
185. Van Langen, L.M., van Rantwijk, F. and Sheldon, R.A., Enzymatic hydrocyanation of a sterically hindered aldehyde. Optimization of a chemoenzymatic procedure for (R)-2-chloromandelic acid. Org. Proc. Res. Dev., 7, 2003, 7-828.
186. Gijsen, H.J.M., Wong, C.-H., Unprecedented asymmetric aldol reactions with three aldehyde substrates catalyzed by 2-deoxyribose-5-phosphate aldolase. J. Am. Chem. Soc., 116, 1994, 116-8422.
187. Wong, C.-H., Garcia Junceda, E., Chen, L., Blanco, O., Gijsen, H.J.M. and Steensma, D.H., Recombinant 2-deoxyribose-5-phosphate aldolase in organic synthesis: use of sequential two-substrate and three-substrate aldol reactions. J. Am. Chem. Soc., 117, 1995, 117-3333.
188. DeSantis, G., Liu, J., Clark, D.P., Heine, A., Wilson, I.A. and Wong, C.-H., Structure-based mutagenesis approaches toward expanding the substrate specificity of D-2-deoxyribose-5-phosphate aldolase. Bioorg. Med. Chem., 11, 2003, 11-43.
189. Liu, J., Hsu, C.-C. and Wong, C.-H., Sequential aldol condensation catalyzed by DERA mutant Ser238Asp and a formal total synthesis of atorvastatin. Tetrahedron Lett., 45, 2004, 45-2439.
190. Hu, S., Tao, J. and Xie, Z., Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof. PTC Int. Appl., 2006, WO 2006/134482 A1.
191. Liu, J. and Wong C.-H., Aldolase-catalyzed asymmetric synthesis of novel pyranose synthons as a new entry to heterocycles and epothilones. Angew. Chem. Int. Ed., 41, 2002, 41-1404.
192. Samland, A.K. and Sprenger, G.A., Microbial aldolases as C-C bonding enzymes-unknown treasures and new developments. Appl. Microbiol. Biotechnol., 71, 2006, 71-253.
193. Schürmann, M. and Sprenger, G.A., Fructose-6-phosphate aldolase is a novel Class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases. J. Biol. Chem., 276, 2001, 276-11055.
194. Sugiyama, M., Hong, Z., Whalen, L.J., Greenberg, W.A. and Wong, C.-H., Borate as a phosphate ester mimic in aldolase-catalyzed reactions: practical synthesis of L-fructose and L-iminocyclitols. Adv. Synth. Catal. 2006, 348, 2555-2559.
195. Griebenow, K. and Klibanov, A.M., On protein denaturation in aqueous-organic mixtures but not in pure organic solvents. J. Am. Chem. Soc., 118, 1996, 118-11695.
196. For some recent reviews on the use of enzymes in nonconventional media, see: Dreyer, S., Lembrecht, J., Schumacher, J. and Kragl, U., Enzyme catalysis in nonaqueous media: past, present, and future in biocatalysis in the pharmaceutical and biotechnology industries, 2007, CRC Press, pp. 791-827.
197. Torres, S. and Castro, G.R., Non-aqueous biocatalysis in homogeneous solvent systems. Food Technol. Biotechnol., 42, 2004, 42-271.
198. Carrea, G. and Riva, S., Properties and synthetic applications of enzymes in organic solvent. Angew. Chem. Int. Ed., 39, 2000, 39-2226.
199. Butler, L.G., Enzymes in non-aqueous solvents. Enzyme Microb. Technol., 1, 1979, 1-253.
200. Gerard A. Sellek, G.A. and Chaudhuri, J.B., Biocatalysis in organic media using enzymes from extremophiles. Enzyme Microb. Technol., 25, 1999, 25-471.
201. Van Rantwijk, F. and Sheldon, R.A., Biocatalysis in ionic liquids. Chem. Rev., 107, 2007, 107-2757.
202. Hobbs, H.R. and Thomas, N.R., Biocatalysis in supercritical fluids, in fluorous solvents, and under solvent-free conditions. Chem. Rev., 107, 2007, 107-2786.
203. Kazlauskas, R.J., Enhancing catalytic promiscuity for biocatalysis. Curr. Opin. Chem. Biol., 9, 2005, 9-1.
204. Gruber-Khadjawi, M., Purkarthofer, T., Skranc, W. and Griengl, H., hydroxynitrile lyase catalyzed enzymatic nitroaldol (Henry) reaction. Adv. Synth. Catal. 2007, 349, 1445-1450.
205. Torre, O., Alfonso, I. and Gotor, V., Lipase catalysed Michael addition of secondary amines to acrylonitrile. Chem. Commun., 2004, 1724-1725.
206. Cai, Y., Yao, S.-P., Wu, Q. and Lin, X.-F., Michael addition of imidazole with acrylates catalyzed by alkaline protease from Bacillus subtilis in organic media. Biotechnol. Lett., 26, 2004, 26-525.
207. Zaks, A. and Klibanov, A.M., Enzymatic catalysis in organic media at 100 βC. Science, 224, 1984, 224-1249.
208. Griebenow, K. and Barletta, G., Dehydrated protein powders as biocatalysts in nonaqueous solvents. In Lyophilization of Biopharmaceuticals (Biotechnology: Pharmaceutical Aspects), Costantino, H.R. and Pikal, M.J. (eds). AAPS Press: Arlington, VA, 2004, pp. 643-668.
209. Klibanov, A.M., Why are enzymes less active in organic solvents than in water? Trends Biotechnol. 1997, 15, 97-101.
210. Klibanov, A.M., Improving enzymes by using them in organic solvents. Nature, 409, 2001, 409-241.
211. Serdakowski, A.L. and Dordick, J.S., Enzyme activation for organic solvents made easy. Trends Biotechnol. 2008, 26, 48-54.
212. Partridge, J., Dennison, P.R., Moore, B.D. and Halling, P.J., Activity and mobility of subtilisin in low water organic media: hydration is more important than solvent dielectric. Biochim. Biophys. Acta, 1386, 1998, 1386-79.
213. Bell, G., Halling, P.J., May, L., Moore, B.D., Robb, D.A., Ulijn, R. and Valivety, R.H., Methods for measurement and control of water in nonaqueous biocatalysis. In Methods in Biotechnology, Vol. 15: Enzymes in Nonaqueous Solvents: Methods and Protocols, Vulfson, E.N., Halling, P.J. and Holland, H.L. (eds). Humana Press: Totowa, NJ, 2001, pp. 105-126.
214. Valivety, R.H., Halling, P.J., Peilow, A.D. and Macrae, A.R., Lipases from different sources vary widely in dependence of catalytic activity on water activity. Biochim. Biophys. Acta, 1122, 1992, 1122-143.
215. Halling, P.J., What can we learn by studying enzymes in non-aqueous media? Phil. Trans. R. Soc. Lond. Ser. B, 359, 2004, 359-1287.
216. Bell, G., Halling, P.J., Moore, B.D., Partridge, J. and Rees, D.G., Biocatalyst behaviour in lowwater systems. Trends Biotechnol., 13, 1995, 13-468.
217. Rich, J.O., Mozhaev, V.V., Dordick, J.S., Clark, D.S. and Khmelnitsky, Y.L., Molecular imprinting of enzymes with water-insoluble ligands for nonaqueous biocatalysis. J. Am. Chem. Soc., 2002, 124, 5254-5255 and references cited therein.
218. Carrea, G., Ottolina, G. and Riva, S., Role of solvents in the control of enzyme selectivity in organic media. Trends Biotechnol. 1995, 13, 63-70 and references cited therein.
219. Zacharis, E., Moore, B.D. and Halling, P.J., Control of enzyme activity in organic media by solid-state acid-base buffers. J. Am. Chem. Soc., 119, 1997, 119-12396.
220. Zaks, A. and Klibanov, A.M., Enzyme-catalyzed processes in organic solvents. Proc. Natl. Acad. Sci., 42, 1985, 42-3192.
221. Laane, C., Boeren, S., Vos, K. and Veeger, C., Rules for optimization of biocatalysis in organic solvents. Biotechnol. Bioeng., 30, 1987, 30-81.
222. Halling, P.J., Thermodynamic predictions for biocatalysis in nonconventional media: theory, tests, and recommendations for experimental design and analysis. Enzyme Microb. Technol., 16, 1994, 16-178.
223. Secundo, F., Riva, S. and Carrea, G., Effects of medium and of reaction conditions on the enantioselectivity of lipases in organic solvents and possible rationales, Tetrahedron Asymm. 1992, 3, 267-280.
224. Keeling, S.P., Campbell, I.B., Coe, D.M., Cooper, T.W.J., Hardy, G.W., Jack, T.I., Jones, H.T., Needham, D., Shipley, T.J., Skone, P.A., Sutton, P.W., Weingarten G.A. and Macdonald, S.J.F., Efficient synthesis of an α-trifluoromethyl-α-tosyloxymethyl epoxide enabling stepwise double functionalisation to afford CF3-substituted tertiary alcohols. Tetrahedron Lett. 2008, 49, 5101.
225. Roberge, C., Fleitz, F., Pollard, D. and Devine, P., Asymmetric synthesis of cyanohydrin derived from pyridine aldehyde with cross-linked aggregates of hydroxynitrile lyases. Tetrahedron Lett., 48, 2007, 48-1473.
226. Hirose, Y., Kariya, K., Sasaki, I., Kurono, Y., Ebiike, H. and Achiwa, K., Drastic solvent effect on lipase-catalysed enantioselective hydroloysis of prochiral 1,4-dihydropyridines. Tetrahedron Lett., 33, 1992, 33.
227. Ballesteros, A., van Beynum, G., Borud, O. and Buchholz, K., Guidelines for the characterization of immobilized biocatalysts. Enzyme Microb. Technol., 5, 1983, 5-304.
228. For some recent reviews, see: Pčenosil, J.E., Kut,ö .M., Dunn, I.J. and Heinzle, E., Immobilized biocatalysts. In Ullman's Biotechnology and Biochemical Engineering, vol. 2. Wiley-VCH, Weinheim, 2007, pp. 683-734.
229. Sheldon, R.A., Enzyme immobilization: the quest for optimum performance. Adv. Synth. Catal., 349, 2007, 349-1289.
230. End, N. and Schöning, K.-U., Immobilized biocatalysts in industrial research and production. Topics Curr. Chem., 242, 2004, 242-273.
231. Bornscheuer, U.T., Immobilizing enzymes: how to create more suitable biocatalysts. Angew. Chem. Int. Ed., 42, 2003, 42-3336.
232. Cao, L. Immobilised enzymes: science or art? Curr. Opin. Chem. Biol., 2005, 9, 217-226.
233. Schmid, R.D. and Verger, R., Lipases: interfacial enzymes with attractive application. Angew. Chem. Int. Ed., 1998, 37, 1608-1633;
234. Hasan, F., Shah, A.A. and Hameed, A., Industrial applications of microbial lipases. Enzyme. Microb. Technol., 39, 2006, 39-235.
235. González-Navarro, H., Carmen Bañó, M. and Abad, C., The closed/open model for lipase activation. Addressing intermediate active forms of fungal enzymes by trapping of conformers in water-restricted environments. Biochemistry, 40, 2001, 40-3174.
236. Katchalski-Katzir, E. and Kraemer, D.M., Eupergitγ C, a carrier for immobilization of enzymes of industrial potential. J. Mol. Catal. B, 10, 2000, 10-157.
237. Roy, J.J. and Abraham, T.E., Strategies in making cross-linked enzyme crystals. Chem. Rev., 104, 2004, 104-3705.
238. Weetall, H.H. and Pitcher Jr, W.H., Scaling up an immobilized enzyme system. Science, 232, 1986, 232-1396.
239. Schoevaart, R., Wolbers, M.W., Golubovic, M., Ottens, M., Kieboom, A.P.G., van Rantwijk, F., van der Wielen, L.A.M. and Sheldon, R.A., Preparation, optimization, and structures of cross-linked enzyme aggregates (CLEAs). Biotechnol. Bioeng., 87, 2004, 87-754.
240. Mateo, C., Palomo, J.M., van Lancen, L.M., van Rantwijk, F. and Sheldon, R.A., A new, mild cross-linking methodology to prepare cross-linked enzyme aggregates. Biotech. Bioeng., 86, 2004, 86-273.
241. Dunker, A.K. and Fernández, A., Engineering productive enzyme confinement. Trends Biotechnol., 25, 2007, 25-189.
242. Pierre, A.C., The sol-gel encapsulation of enzymes. Biocatal. Biotrans., 2004, 22, 145-170 and references cited therein.
243. Reetz, M.T., Tielmann, P., Wiesenhöfer, W., Könen, W. and Zonta, A., Second generation sol-gel encapsulated lipases: robust heterogeneous biocatalysts. Adv. Synth. Catal., 345, 2003, 345-717.
244. Lütz, S., Rao, N.N. and Wandrey, C., Membranes in biotechnolog. Chem. Eng. Technol., 2006, 29, 1404-1415;
245. Gekas, V.C., Artificial membranes as carriers for the immobilization of biocatalysts. Enzyme Microb. Technol., 8, 1986, 8-450.
246. Anastas, P.T. and Warner, J.C., Green Chemistry: Theory and Practice, Oxford University Press, 2000.
247. Sheldon, R.A., Organic synthesis-past, present and future. Chem. Ind., 23, 1992, 23-903.
248. Constable, D.J.C., Curzons, A.D. and Cunningham, V.L., Metrics to 'green chemistry'-which are the best? Green Chem. 2002, 4, 521-527.
249. ACS GCI Pharmaceutical Roundtable, http://portal.acs.org/portal/acs/corg/content?_nfpb1/4true&_pageLabel1/4PP_TRANSITIONMAIN&node_id1/41422&use_sec1/4false&sec_url_var1/4region1, (last access 24 June 2008).
250. Constable, D.J.C., Curzons, A.D., Freitas dos Santos, L.M., Geen, G.R., Kitteringham, J., Smith, P., Hannah, R.E., McGuire, M.A., Webb, R.L., Yu, M., Hayler, J.D. and Richardson, J.E., Green chemistry measures for process research and development. Green Chem., 3, 2001, 3-7.
251. Curzons, A.D., Constable, D.J.C., Mortimera, D.N. and Cunningham, V.L., So you think your process is green, how do you know? Using principles of sustainability to determine what is green-a corporate perspective. Green Chem., 3, 2001, 3-1.
252. Jiménez González, C., Curzons, A.D., Constable, D.J.C. and Cunningham, V.L., Cradle-to-gate life cycle inventory and assessment of pharmaceutical compounds. Int. J. Life Cycle Assess., 9, 2004, 9-115.
253. Curzons, A.D., Jiménez González, C., Duncan, A.L., Constable, D.J.C. and Cunningham, V.L., Fast life cycle assessment of synthetic chemistry (FLASC) tool. Int. J. Life Cycle Assess., 12, 2007, 12-272.
254. Jiménez González, C., Overcash, M.R. and Curzons, A., Waste treatment modules-a partial life cycle inventory. J. Chem. Technol. Biotechnol., 76, 2001, 76-707.
255. Jiménez González, C., Constable, D.J.C., Curzons, A.D. and Cunningham, V.L., Developing GSK's green technology guidance: methodology for case-scenario comparison of technologies. Clean Technol. Environ. Pollut., 4, 2002, 4-44.
256. Sheldon, R.A., The E factor: fifteen years on. Green Chem., 9, 2007, 9-1273.
257. Menzel, A., Werner, H., Altenbuchner, J. and Groeger, H., From enzymes to 'designer bugs' in reductive amination: a new process for the synthesis of L-tert-leucine using a whole cellcatalyst. Eng. Life Sci., 4, 2004, 4-573.
258. Bruggink, A., Schoevaart, R. and Kieboom, T., Concepts of nature in organic synthesis: cascade catalysis and multistep conversions in concert. Org. Proc. Res. Dev., 7, 2003, 7-622.
259. Buckland, B.C., Robinson, D.K. and Chartrain, M., Biocatalysis for pharmaceuticals-status and prospects for a key technology. Metab. Eng., 2, 2000, 2-42.
260. Bacher, A., Stohler, P. and Weber, W., Process for the production of lipstatin and tetrahydrolipstatin. Eur. Pat. Appl., 2002, EP803576 A2.
261. Fleming, M.P., Han, Y.-K., Hodges, L.M., Johnston, D.A., Micheli, R.P., Puentener, K., Roberts, C.R., Scalone, M., Schwindt, M.A. and Topping, R.J., Process for the (enantioselective) synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-ones via intramolecular cyclization of (homochiral) α-halo esters. PCT Int. Appl., 2001, WO 2001057014 A2.
262. Birk, R., Karpf, M., Püntener, K., Scalone,M., Schwindt,M. and Zutter, U., With asymmetric hydrogenation towards a new, enantioselective synthesis of orlistat. Chimia, 60, 2006, 60-561.
263. Schwindt, M.A., Fleming,M.P., Han, Y.-K., Hodges, L.M., Johnston, D.A., Micheli, R.P., Roberts, C.R., Snyder, R., Topping,R.J., Püntener, K. and Scalone, M., enantioselective synthesis of a key intermediate in a new process for orlistat using asymmetric hydrogenation and a Grignard reagent promoted lactone cyclization. Org. Proc. Res. Dev., 11, 2007, 11-524.
264. Karpf, M. and Zutter, U., Process for the preparation of oxetanones. Eur. Pat. Appl., 1991, EP 443449 A2.
265. The chemical route to orlistat was ultimately favoured over the biosynthetic route as the latter required complex downstream processing that eliminated the benefits gained from the biotransformation itself. More recent advances in metabolic engineering and drownstream processing might have resulted in the development of a more competitive process.
266. Poechlauer, P. and Wagner, M., Enzymatic process to separate racemic mixtures of delta valerolactones. US PCT Appl., 1995, US 5412110.
267. Scott, A.I., Discovering nature's diverse pathways to vitamin B12: a 35-year odyssey. J. Org. Chem., 68, 2003, 68-2529.
268. Bornscheuer, U.T. and Buchholz, K., Highlights in biocatalysis-historical landmarks and current trends. Eng. Life Sci., 5, 2005, 5.